JP2016522188A5 - - Google Patents

Download PDF

Info

Publication number
JP2016522188A5
JP2016522188A5 JP2016512076A JP2016512076A JP2016522188A5 JP 2016522188 A5 JP2016522188 A5 JP 2016522188A5 JP 2016512076 A JP2016512076 A JP 2016512076A JP 2016512076 A JP2016512076 A JP 2016512076A JP 2016522188 A5 JP2016522188 A5 JP 2016522188A5
Authority
JP
Japan
Prior art keywords
entinostat
administration
administered
conditions
combination according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2016512076A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016522188A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/036651 external-priority patent/WO2014179738A1/en
Publication of JP2016522188A publication Critical patent/JP2016522188A/ja
Publication of JP2016522188A5 publication Critical patent/JP2016522188A5/ja
Pending legal-status Critical Current

Links

JP2016512076A 2013-05-03 2014-05-02 癌の処置方法 Pending JP2016522188A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361819505P 2013-05-03 2013-05-03
US61/819,505 2013-05-03
PCT/US2014/036651 WO2014179738A1 (en) 2013-05-03 2014-05-02 Methods for the treatment of cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019026073A Division JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Publications (2)

Publication Number Publication Date
JP2016522188A JP2016522188A (ja) 2016-07-28
JP2016522188A5 true JP2016522188A5 (enExample) 2017-06-15

Family

ID=51843995

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016512076A Pending JP2016522188A (ja) 2013-05-03 2014-05-02 癌の処置方法
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019026073A Active JP6860949B2 (ja) 2013-05-03 2019-02-15 癌の処置方法

Country Status (6)

Country Link
EP (1) EP2991650A4 (enExample)
JP (2) JP2016522188A (enExample)
KR (1) KR102337598B1 (enExample)
CN (1) CN105492007A (enExample)
HK (1) HK1223547A1 (enExample)
WO (1) WO2014179738A1 (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017028287A2 (en) * 2015-06-29 2018-09-04 Syndax Pharmaceuticals, Inc. COMBINATION OF THE HDAC INHIBITOR AND ANTICORPIDE ANTI-PD- L1 FOR CANCER TREATMENT
JP2019524748A (ja) * 2016-07-20 2019-09-05 エーザイ・アール・アンド・ディー・マネジメント株式会社 がんの治療におけるエリブリン及びヒストンデアセチラーゼ阻害剤の使用
JP7537874B2 (ja) 2017-05-19 2024-08-21 シンダックス ファーマシューティカルズ, インコーポレイテッド 併用療法
US12156866B2 (en) 2018-06-06 2024-12-03 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the S1P1 receptor
RU2680603C1 (ru) * 2018-11-08 2019-02-25 Ильясов Шамиль Сионович Применение 3-о-сульфамата-16,16-диметил-d-гомоэквиленина для лечения онкологических заболеваний

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2006223086A1 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Colorado Histone deacetylase inhibitors sensitize cancer cells to epidermal growth factor inhibitors
EP2046299A1 (en) * 2006-07-11 2009-04-15 Mutual Pharmaceutical Company, Inc. Controlled-release formulations
US20100305167A1 (en) * 2007-11-19 2010-12-02 Syndax Pharmaceuticals, Inc. Administration of an Inhibitor of HDAC
BRPI0909818A2 (pt) * 2008-03-07 2015-10-06 Pfizer métodos, formas de dosagem e conjunto para administrar ziprasidona sem alimentos
CA2725390C (en) * 2008-04-08 2014-09-23 Syndax Pharmaceuticals, Inc. Use of a hdac inhibitor and a her-2 inhibitor in the treatment of breast cancer
JP6195384B2 (ja) * 2011-09-02 2017-09-13 シンダックス ファーマシューティカルズ,インク. 乳癌の処置方法

Similar Documents

Publication Publication Date Title
JP2019112416A5 (enExample)
WO2017042607A3 (en) Compositions comprising meloxicam-cyclodextrin inclusion complexes and methods of treating acute pain
JP2012193216A5 (enExample)
JP2016522188A5 (enExample)
WO2014205229A8 (en) Use of high dose pridopidine for treating huntington's disease
MX2019013279A (es) Metodos de tratamiento del sindrome de doose utilizando fenfluramina.
JP2014528901A5 (enExample)
ZA202301198B (en) Method of treating diseases
JP2016520089A5 (enExample)
HK1206246A1 (en) Use of high dose laquinimod for treating multiple sclerosis
JP2016510326A5 (enExample)
JP2014503593A5 (enExample)
AR091351A1 (es) Formulaciones de bromocriptina, metodo para mejorar el control glucemico y metodo para la fabricacion
NZ744323A (en) Compositions comprising 15-hepe and methods of using the same
JP2016512817A5 (enExample)
JP2015532293A5 (ja) 糖尿病患者における心不全の治療用組成物
JP2015522603A5 (enExample)
JP2017514858A5 (enExample)
RU2018146504A (ru) Лечение внутрипеченочных холестатических заболеваний
JP2016501234A5 (enExample)
JP2019528267A5 (enExample)
JP2017061488A5 (enExample)
JP2015535256A5 (enExample)
SG10201809673RA (en) Treatment of androgen deprivation therapy associated symptoms
TW201613600A (en) Piperazinyl derivative reduces HFD-induced accumulation of fat in the liver, therapeutically